Internal Advisory Committee Along with Drs. Ahles, Hubbard, Gany and Trevisan, members of the Internal Advisory Committee (IAC) provide major academic leadership and support for the Partnership. The members of the IAC have diverse backgrounds that map onto areas of strength in our translational research and training portfolio: health disparities, biomedical engineering, and basic science. The IAC will meet quarterly to review progress of research projects and training and outreach cores, and will have oversight responsibility of effective mentorship of junior faculty and trainees. The IAC will also be actively involved in the identification of external reviewers for grants submitted for consideration for U54 funding, and decision-making regarding which grants to fund following external review. Program Steering Committee The Program Steering Committee (PSC) will continue to meet annually, about six to eight weeks before the annual progress report is due, to review the progress and priorities of our Partnership. We will also hold an annual teleconference (more as needed) with the PSC to keep members up to date and to discuss emerging opportunities and issues. We are fortunate to have retained six of our seven members of our Program Steering Committee (Drs. Ozer, Bayliss, Munn, Vernon, Trickett, and Lepore). Only Dr. Gany has left the PSC, since she joined MSKCC and is now co-PI of the Partnership at MSKCC. Several of these senior scientists have been guiding us since we prepared our U56 proposal in 2001 and the subsequent U54, and have been instrumental in reviewing our work at every stage of development of the U54. In addition, we have allocated funds for various ad hoc members to join the PSC as needed, as our transdisciplinary work in cancer disparities takes shape and direction. Executive Advisory Committee During the U54 we formed an Executive Advisory Committee to ensure that the Partnership was fully integrated into CCNY and MSKCC institutional priorities and to address the Partnership's needs. We will continue to meet with our Executive Advisory Committee annually, bringing together senior leadership from both MSKCC and CCNY to discuss relevant developments, opportunities and concerns. Although the senior leadership at both MSKCC and CCNY have changed during the U54, we have engaged the new President of CCNY and new Physician-in-Chief at MSKCC, both of whom agreed join our Executive Advisory Committee

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Yeh, Yi-Chen; Nitadori, Jun-ichi; Kadota, Kyuichi et al. (2015) Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ? 3 cm: accuracy and interobserver agreement. Histopathology 66:922-38
Mandelblatt, Jeanne S; Jacobsen, Paul B; Ahles, Tim (2014) Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 32:2617-26
Guidry, John A; Lubetkin, Erica; Corner, Geoffrey et al. (2014) Promoting cancer prevention and control in community-based HIV/AIDS service organizations: are they ready? AIDS Educ Prev 26:43-55
Kadota, Kyuichi; Yeh, Yi-Chen; Sima, Camelia S et al. (2014) The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol 27:690-700
Eguchi, Takashi; Kadota, Kyuichi; Park, Bernard J et al. (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210-22
Dereli-Korkut, Zeynep; Akaydin, H Dogus; Ahmed, A H Rezwanuddin et al. (2014) Three dimensional microfluidic cell arrays for ex vivo drug screening with mimicked vascular flow. Anal Chem 86:2997-3004
Lee, Ming-Ching; Buitrago, Daniel H; Kadota, Kyuichi et al. (2014) Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. Lung Cancer Manag 3:245-253
Kachala, Stefan S; Bograd, Adam J; Villena-Vargas, Jonathan et al. (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20:1020-8
de Biasi, Andreas R; Villena-Vargas, Jonathan; Adusumilli, Prasad S (2014) Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20:5384-91
Lubetkin, Erica I; Zabor, Emily C; Brennessel, Debra et al. (2014) Beyond demographics: differences in patient activation across new immigrant, diverse language subgroups. J Community Health 39:40-9

Showing the most recent 10 out of 38 publications